| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HBm |
| Uniprot No | Q6B0K9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-141aa |
| 氨基酸序列 | MLSAQERAQI AQVWDLIAGH EAQFGAELLL RLFTVYPSTK VYFPHLSACQ DATQLLSHGQ RMLAAVGAAV QHVDNLRAAL SPLADLHALV LRVDPANFPL LIQCFHVVLA SHLQDEFTVQ MQAAWDKFLT GVAVVLTEKY R |
| 预测分子量 | 15,6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HBm重组蛋白的假设性参考文献示例(基于常见研究方向，非真实文献)：
---
1. **文献名称**: "Efficient expression and purification of recombinant HBm antigen in *Pichia pastoris*"
**作者**: Zhang L. et al.
**摘要**: 研究利用毕赤酵母表达系统高效分泌表达HBm(乙肝病毒中表面抗原)重组蛋白，通过优化密码子和发酵条件提高产量，纯化产物在小鼠模型中显示良好免疫原性。
2. **文献名称**: "HBm recombinant protein-based diagnostic kit for hepatitis B detection"
**作者**: Chen Y., Wang H.
**摘要**: 开发基于HBm重组蛋白的ELISA检测试剂盒，验证其在乙肝患者血清样本中的灵敏度和特异性，对比传统方法显示更高诊断准确性。
3. **文献名称**: "Structural and functional characterization of HBm protein for vaccine development"
**作者**: Smith J., Lee R.
**摘要**: 解析HBm重组蛋白的晶体结构，揭示其抗原表位特征，并通过动物实验证明其作为亚单位疫苗候选株可诱导中和抗体反应。
---
**注**：以上为模拟文献，实际引用时需查询真实数据库(如PubMed、ScienceDirect)并核实原文信息。
HBm recombinant protein, derived from the hepatitis B virus (HBV) middle surface antigen (MHBs), is a engineered protein widely used in biomedical research and diagnostic applications. HBV encodes three envelope proteins: large (LHBs), middle (MHBs), and small (SHBs) surface antigens. The MHBs consists of the pre-S2 domain fused to the S domain, containing critical antigenic epitopes involved in viral attachment and host immune recognition.
Recombinant HBm is typically produced through heterologous expression systems like *E. coli*, yeast, or mammalian cells (e.g., CHO), enabling scalable production while maintaining native conformational epitopes. Its production eliminates infectious risks associated with whole viruses, making it safer for research and therapeutic development. The protein is extensively purified to remove host cell contaminants, ensuring high specificity for immunological applications.
Key applications include:
1. **Diagnostics**: As a coating antigen in ELISA kits to detect HBV-specific antibodies, aiding in infection status assessment and vaccine efficacy monitoring.
2. **Vaccine Development**: Serving as an immunogen to study neutralizing antibody responses and evaluate next-generation vaccine candidates.
3. **Basic Research**: Investigating HBV entry mechanisms, host-virus interactions, and antigenic variations across genotypes.
HBm's pre-S2 domain is particularly valuable, as it harbors binding sites for hepatocyte receptors and contains immunodominant regions. However, antigenic variability across HBV genotypes (A-H) necessitates careful selection of recombinant HBm sequences to match regional viral strains. Ongoing research focuses on optimizing its glycosylation patterns and thermostability to enhance diagnostic accuracy and vaccine design. As HBV remains a global health burden (affecting ~296 million people worldwide), HBm recombinant protein continues to be a vital tool in combating hepatitis B.
×
